177 related articles for article (PubMed ID: 17266609)
1. Pharmacologic modulators of soluble guanylate cyclase/cyclic guanosine monophosphate in the vascular system - from bench top to bedside.
Jackson EB; Mukhopadhyay S; Tulis DA
Curr Vasc Pharmacol; 2007 Jan; 5(1):1-14. PubMed ID: 17266609
[TBL] [Abstract][Full Text] [Related]
2. Structure and regulation of soluble guanylate cyclase.
Derbyshire ER; Marletta MA
Annu Rev Biochem; 2012; 81():533-59. PubMed ID: 22404633
[TBL] [Abstract][Full Text] [Related]
3. Novel therapies for cyclic GMP control of vascular smooth muscle growth.
Tulis DA
Am J Ther; 2008; 15(6):551-64. PubMed ID: 19127140
[TBL] [Abstract][Full Text] [Related]
4. Cyclic guanosine monophosphate in the regulation of the cell function.
Zbrojkiewicz M; Śliwiński L
Postepy Hig Med Dosw (Online); 2016 Dec; 70(0):1276-1285. PubMed ID: 28026830
[TBL] [Abstract][Full Text] [Related]
5. Molecular variants of soluble guanylyl cyclase affecting cardiovascular risk.
Wobst J; Rumpf PM; Dang TA; Segura-Puimedon M; Erdmann J; Schunkert H
Circ J; 2015; 79(3):463-9. PubMed ID: 25746521
[TBL] [Abstract][Full Text] [Related]
6. Inhaled nitric oxide decreases pulmonary soluble guanylate cyclase protein levels in 1-month-old lambs.
Thelitz S; Bekker JM; Ovadia B; Stuart RB; Johengen MJ; Black SM; Fineman JR
J Thorac Cardiovasc Surg; 2004 May; 127(5):1285-92. PubMed ID: 15115984
[TBL] [Abstract][Full Text] [Related]
7. Soluble guanylyl cyclase: more secrets revealed.
Pyriochou A; Papapetropoulos A
Cell Signal; 2005 Apr; 17(4):407-13. PubMed ID: 15601619
[TBL] [Abstract][Full Text] [Related]
8. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
Boerrigter G; Burnett JC
Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086
[TBL] [Abstract][Full Text] [Related]
9. Regulation of the expression of soluble guanylyl cyclase by reactive oxygen species.
Gerassimou C; Kotanidou A; Zhou Z; Simoes DC; Roussos C; Papapetropoulos A
Br J Pharmacol; 2007 Apr; 150(8):1084-91. PubMed ID: 17339839
[TBL] [Abstract][Full Text] [Related]
10. Regulation of nitric oxide and soluble guanylyl cyclase.
Krumenacker JS; Hanafy KA; Murad F
Brain Res Bull; 2004 Feb; 62(6):505-15. PubMed ID: 15036565
[TBL] [Abstract][Full Text] [Related]
11. Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence.
Stasch JP; Schlossmann J; Hocher B
Curr Opin Pharmacol; 2015 Apr; 21():95-104. PubMed ID: 25645316
[TBL] [Abstract][Full Text] [Related]
12. Riociguat for the treatment of pulmonary hypertension.
Hambly N; Granton J
Expert Rev Respir Med; 2015; 9(6):679-95. PubMed ID: 26599488
[TBL] [Abstract][Full Text] [Related]
13. The chemistry and biology of soluble guanylate cyclase stimulators and activators.
Follmann M; Griebenow N; Hahn MG; Hartung I; Mais FJ; Mittendorf J; Schäfer M; Schirok H; Stasch JP; Stoll F; Straub A
Angew Chem Int Ed Engl; 2013 Sep; 52(36):9442-62. PubMed ID: 23963798
[TBL] [Abstract][Full Text] [Related]
14. Novel approaches and opportunities for cardioprotective signaling through 3',5'-cyclic guanosine monophosphate manipulation.
Bice JS; Burley DS; Baxter GF
J Cardiovasc Pharmacol Ther; 2014 May; 19(3):269-82. PubMed ID: 24572031
[TBL] [Abstract][Full Text] [Related]
15. Expression and activity of soluble guanylate cyclase in injury and repair of anti-thy1 glomerulonephritis.
Peters H; Wang Y; Loof T; Martini S; Kron S; Krämer S; Neumayer HH
Kidney Int; 2004 Dec; 66(6):2224-36. PubMed ID: 15569311
[TBL] [Abstract][Full Text] [Related]
16. Receptor-controlled phosphorylation of alpha 1 soluble guanylyl cyclase enhances nitric oxide-dependent cyclic guanosine 5'-monophosphate production in pituitary cells.
Kostic TS; Andric SA; Stojilkovic SS
Mol Endocrinol; 2004 Feb; 18(2):458-70. PubMed ID: 14630997
[TBL] [Abstract][Full Text] [Related]
17. Antigrowth properties of BAY 41-2272 in vascular smooth muscle cells.
Mendelev NN; Williams VS; Tulis DA
J Cardiovasc Pharmacol; 2009 Feb; 53(2):121-31. PubMed ID: 19188837
[TBL] [Abstract][Full Text] [Related]
18. Escherichia coli lipopolysaccharide downregulates soluble guanylate cyclase in pulmonary artery smooth muscle.
Scott WS; Nakayama DK
J Surg Res; 1998 Dec; 80(2):309-14. PubMed ID: 9878330
[TBL] [Abstract][Full Text] [Related]
19. Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis.
Wang Y; Krämer S; Loof T; Martini S; Kron S; Kawachi H; Shimizu F; Neumayer HH; Peters H
Kidney Int; 2005 Jul; 68(1):47-61. PubMed ID: 15954895
[TBL] [Abstract][Full Text] [Related]
20. [Nitric oxide. Potentiation of NO-dependent activation of soluble guanylate cyclase--(patho)physiological and pharmacotherapeutical significance].
Severina IS
Biomed Khim; 2007; 53(4):385-99. PubMed ID: 18035720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
